Sintilimab plus decitabine for higher-risk treatment-naïve myelodysplastic syndromes: efficacy, safety, and biomarker analysis of a phase II, single-arm trial
Journal for ImmunoTherapy of Cancer · 2024-11 · 12 (11) · e010355
DOI: 10.1136/jitc-2024-010355 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 21.11.2024. Verfasst von Jing Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Peking University Institute of Hematology. National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Ce…. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Decitabine, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Science Foundation of China.
Abstract (Originalsprache)
Background
Immunotherapy combined with azacitidine was feasible in higher-risk myelodysplastic syndromes (MDSs) with limited sample size of treatment-naïve patients, while the optimization of treatment strategies, including the optimal immune checkpoint inhibitor and hypomethylating agent and possible benefiting population, remained undefined. This study first evaluates the efficacy and safety of sintilimab, a PD-1 blockade, plus decitabine in treatment-naïve higher-risk MDS patients and investigates biomarkers for predicting treatment response.
Methods
In this phase II, single-arm trial (ChiCTR2100044393), treatment-naïve higher-risk MDS patients with an International Prognostic Scoring System-Revised score >3.5 received sintilimab (200 mg, days 1 and 22) and decitabine (20 mg/m 2 , day 1–5) over 6-week cycles. The primary endpoint was the overall response rate (ORR), including complete remission (CR), partial remission (PR) or marrow CR.
Results
A total of 54 eligible patients were enrolled and treated, with 25 (46.3%) having very high-risk MDS. Among 53 evaluable patients, the ORR was 77.4% (n=41), including 26.4% CR (n=14). The overall clinical improvement rate (CR, PR, marrow CR or hematological improvement) reached 81.1%. With a median follow-up of 20.0 months, the median event-free survival was 23 months with 12 progressing to acute myeloid leukemia. Median overall survival was not reached. Treatment was generally well tolerated, with hematologic toxicities being the most common adverse events. Biomarker analysis highlighted a negative correlation between T cell exhaustion markers, particularly TIM-3 and PD-1, with ORR.
Conclusions
The combination of sintilimab and decitabine shows promise efficacy for higher-risk MDS, with a favorable safety profile. The potential predictive value of T cell exhaustion biomarkers might help screen the possible benefiting population. Trial registration number ChiCTR210044393.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peking University Institute of Hematology. National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, Chin…
- Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Sciences, Beijing, China.
ORCID-Profile: Xiaojun Huang
Förderung
- National Science Foundation of China
Zitieren
APA
Wang, J., Li, S., Jiang, H., Chang, Y. J., Zhao, X., Jia, J., Zhu, X., Gong, L., Liu, X., Yu, W., & Huang, X. (2024). Sintilimab plus decitabine for higher-risk treatment-naïve myelodysplastic syndromes: efficacy, safety, and biomarker analysis of a phase II, single-arm trial. Journal for ImmunoTherapy of Cancer, 12(11), e010355. https://doi.org/10.1136/jitc-2024-010355
Vancouver
Wang J, Li S, Jiang H, Chang YJ, Zhao X, Jia J, et al. Sintilimab plus decitabine for higher-risk treatment-naïve myelodysplastic syndromes: efficacy, safety, and biomarker analysis of a phase II, single-arm trial. Journal for ImmunoTherapy of Cancer. 2024;12(11):e010355. doi:10.1136/jitc-2024-010355
BibTeX
@article{Wang2024,
author = {Wang, Jing and Li, Siqi and Jiang, Hao and Chang, Ying-Jun and Zhao, Xiaosu and Jia, Jinsong and Zhu, Xiaolu and Gong, Lizhong and Liu, Xiaohong and Yu, Wenjing and Huang, Xiaojun},
title = {Sintilimab plus decitabine for higher-risk treatment-naïve myelodysplastic syndromes: efficacy, safety, and biomarker analysis of a phase II, single-arm trial},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
volume = {12},
number = {11},
pages = {e010355},
doi = {10.1136/jitc-2024-010355}
}
EUVIMED